Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc. reported a net loss of $26.0 million for the fiscal year ended December 31, 2025, compared to a net loss of $24.1 million in the prior year. The company's loss from operations was $26.3 million, driven by research and development expenses of $14.5 million and general and administrative expenses of $11.8 million. Cash and cash equivalents stood at $21.6 million as of year-end, with a net cash increase of $12.9 million for the year, primarily from $38.5 million in financing activities, including equity offerings. The company's accumulated deficit reached $275.1 million, and management has concluded that substantial doubt exists about its ability to continue as a going concern. Key forward-looking items include the clinical development of mipletamig and ALG.APV-527, reliance on additional funding, and potential milestone payments from Medexus related to IXINITY.

Key Takeaways